Novartis facing board change threat from shareholder following trial failures
A large Novartis NYSE:NVS shareholder is calling for changes on the Swiss pharma giant's board in the aftermath of two phase 3 drug trial setbacks in the last few weeks.Artisan Partners Managing Director David Samra told Reuters that several past chairmen had done a poor job of overseeing M&A activ…